Possible Bioenergetic Biomarker for Chronic Cancer-Related Fatigue.
Possible Bioenergetic Biomarker for Chronic Cancer-Related Fatigue.
复制标题
DOI：
10.1097/nnr.0000000000000547
复制
发表时间：
2021-11-01
期刊：
影响因子：
2.5
通讯作者：
Hoppel C
中科院分区：
文献类型：
--
作者：
Hsiao CP;Daly B;Chen MK;Veigl M;Dorth J;Ponsky LE;Hoppel C
与癌症相关的疲劳是接受癌症治疗的患者所经历的一种非常普遍、令人衰弱且持续的症状。高达 71% 接受放射治疗的前列腺癌男性会经历急性和持续性 CRF。对于与癌症相关的疲劳，既没有有效的治疗方法也没有诊断生物标志物。这项试点研究旨在发现与接受放射治疗的前列腺癌男性慢性癌症相关疲劳相关的潜在生物标志物。我们采用了纵向重复测量研究设计。二十名接受放射治疗的前列腺癌男性完成了所有研究访视。癌症相关疲劳通过完善且经过验证的调查问卷“患者报告结果测量信息系统-疲劳”(PROMIS-F) 简表进行评估。此外，收集外周血单核细胞（PBMC）以量化线粒体相关基因的核糖核酸（RNA）基因表达。在放射治疗之前、期间、完成时和放射治疗后 24 个月收集数据，并使用配对 t 检验和重复测量方差分析进行分析。前列腺癌患者的 PROMIS–F T 评分平均值随着时间的推移显着增加，与基线相比，在放射治疗后 24 个月仍保持较高水平。在放射治疗期间和放射治疗后 24 个月，观察到 BC1 泛醇细胞色素 c 还原酶合成样 (BCS1L) 显着下调。完成放射治疗 24 个月后，患者的 PROMIS-F 评分呈增加趋势，且 BCS1L 下调。这是第一个证据，通过对接受前列腺癌放射治疗的男性使用 PROMIS-F 测量来描述慢性癌症相关疲劳中 BCS1L 信使 RNA 的改变。我们的结果表明，BCS1L 的 PBMC 信使 RNA 是该临床人群中放射治疗引起的慢性癌症相关疲劳的潜在生物标志物和治疗靶点。
Cancer-related fatigue is a highly prevalent, debilitating, and persistent symptom experienced by patients receiving cancer treatments. Up to 71% of men with prostate cancer receiving radiation therapy experience acute and persistent CRF. There is neither an effective therapy nor a diagnostic biomarker for cancer-related fatigue. This pilot study aimed to discover potential biomarkers associated with chronic cancer-related fatigue in men with prostate cancer receiving radiation therapy. We used a longitudinal repeated-measures research design. Twenty men with prostate cancer undergoing radiation therapy completed all study visits. Cancer-related fatigue was evaluated by a well-established and validated questionnaire, the Patient-Reported Outcomes Measurement Information System–Fatigue (PROMIS–F) Short Form. In addition, peripheral blood mononuclear cells (PBMC) were harvested to quantify ribonucleic acid (RNA) gene expression of mitochondria-related genes. Data were collected before, during, on completion, and 24 months postradiation therapy and analyzed using paired t-tests and repeated measures analysis of variance. The mean of the PROMIS–F T-score was significantly increased over time in patients with prostate cancer, remaining elevated at 24 months post-radiation therapy compared to baseline. A significant downregulated BC1 ubiquinol-cytochrome c reductase synthesis-like (BCS1L) was observed over time during radiation therapy and at 24 months postradiation therapy. An increased PROMIS–F score was trended with downregulated BCS1L in patients 24 months after completing radiation therapy. This is the first evidence to describe altered messenger RNA for BCS1L in chronic cancer-related fatigue using the PROMIS–F measure with men receiving radiation therapy for prostate cancer. Our results suggest that PBMC messenger RNA for BCS1L is a potential biomarker and therapeutic target for radiation therapy-induced chronic cancer-related fatigue in this clinical population.